ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition
Open Access
- 9 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 21 (1), 1-11
- https://doi.org/10.1186/s12885-021-08403-5
Abstract
Background Prolactin receptor (PRLR) is an attractive antibody therapeutic target with expression across a broad population of breast cancers. Antibody efficacy, however, may be limited to subtypes with either PRLR overexpression and/or those where estradiol no longer functions as a mitogen and are, therefore, reliant on PRLR signaling for growth. In contrast a potent PRLR antibody-drug conjugate (ADC) may provide improved therapeutic outcomes extending beyond either PRLR overexpressing or estradiol-insensitive breast cancer populations. Methods We derived a novel ADC targeting PRLR, ABBV-176, that delivers a pyrrolobenzodiazepine (PBD) dimer cytotoxin, an emerging class of warheads with enhanced potency and broader anticancer activity than the clinically validated auristatin or maytansine derivatives. This agent was tested in vitro and in vivo cell lines and patient derived xenograft models. Results In both in vitro and in vivo assays, ABBV-176 exhibits potent cytotoxicity against multiple cell line and patient-derived xenograft breast tumor models, including triple negative and low PRLR expressing models insensitive to monomethyl auristatin (MMAE) based PRLR ADCs. ABBV-176, which cross links DNA and causes DNA breaks by virtue of its PBD warhead, also demonstrates enhanced anti-tumor activity in several breast cancer models when combined with a poly-ADP ribose polymerase (PARP) inhibitor, a potentiator of DNA damage. Conclusions Collectively the efficacy and safety profile of ABBV-176 suggest it may be an effective therapy across a broad range of breast cancers and other cancer types where PRLR is expressed with the potential to combine with other therapeutics including PARP inhibitors.Keywords
This publication has 34 references indexed in Scilit:
- Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancerBreast Cancer Research, 2011
- Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agentsMolecular Cancer, 2010
- Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferaseCarcinogenesis: Integrative Cancer Research, 2009
- Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cellsBreast Cancer Research and Treatment, 2007
- A Prospective Study of Plasma Prolactin Concentrations and Risk of Premenopausal and Postmenopausal Breast CancerJournal of Clinical Oncology, 2007
- Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesionsOncogene, 2006
- Inhibition of Transcription Factor Stat5 Induces Cell Death of Human Prostate Cancer CellsOnline Journal of Public Health Informatics, 2003
- Development of potent monoclonal antibody auristatin conjugates for cancer therapyNature Biotechnology, 2003
- Prolactin as a local growth promoter in patients with breast cancer: GCRI experienceEuropean Journal of Surgical Oncology, 2000
- Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancerInternational Journal of Cancer, 1984